On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096  RAPT Therapeutics (NASDAQ:RAPT)  shares, an estimated $46.24 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, FCPM III Services B.V. increased its stake in RAPT Therapeutics (NASDAQ:RAPT) by 1,489,096 shares during the fourth quarter. The estimated value of the new shares acquired was $46.24 million, based on the average unadjust ...

Company Overview - RAPT Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing oral small-molecule therapies for oncology and inflammatory diseases, leveraging a pipeline approach with candidates like RPT193 and FLX475 [5] - The company operates a biopharmaceutical business model aimed at advancing proprietary drug candidates through research, clinical development, and potential commercialization, targeting patients with unmet medical needs [8] Financial Metrics - As of market close on February 17, 2026, RAPT's stock price was $57.84, with a market capitalization of $955.95 million [4] - The company reported a net income of -$105.64 million (TTM) and experienced a one-year price change of 502.5% [4] Recent Developments - On February 17, 2026, OrbiMed Advisors acquired an additional 556,273 shares of RAPT, with an estimated transaction value of $17.28 million, bringing its total holding to 1,642,891 shares valued at $55.64 million [2][6] - RAPT announced an acquisition by GSK for $58 per share, approximately 75% above its stock price of $33.15 on December 31, indicating the high value placed on promising immunology assets [6][7] Drug Development Focus - RAPT is advancing drug candidates targeting inflammatory diseases and immune pathways, with a notable candidate being ozureprubart, aimed at preventing severe allergic reactions, addressing a significant health challenge affecting over 17 million people in the U.S. [7] - The company's strategic focus on immunology-based therapeutics positions it to compete in markets with high unmet medical needs and significant growth potential [5]

Company Highlights - Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has experienced a 76.53% increase in its stock price, reaching $4.62, attributed to progress in its drug pipeline, particularly the Phase 1b trial for ATI-052 targeting atopic dermatitis [1][5] - Corvus Pharmaceuticals, Inc. (CRVS) has seen a remarkable 142.73% increase, with its stock price hitting $19.54, driven by promising results in its eczema treatment and a focus on immuno-oncology therapies, especially its lead product candidate, Mupadolimab [2][5] - RAPT Therapeutics, Inc. (RAPT) saw its stock price increase by 63.83% to $57.50, despite an investigation into potential breaches of fiduciary duty, with investor interest driven by promising drug candidates like RPT193 and FLX475 [3] Market Overview - Recent market movements highlight the dynamic nature of the stock market, with companies across different sectors experiencing rapid changes in valuations [4]